Sep 09, 2021 / 02:15PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Great. Good morning, everybody. Again, I'm Matthew Harrison, one of the biotech analysts here. And very pleased to have Unity with us for our next session.
Before I get started, I just need to read a quick disclosure statement. So please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/research disclosures.
So I thought maybe just to kick us off and get us started, we could talk about the recent data and sort of your -- the implications and outlook for that. And then we can jump into some more detailed Q&A.
Anirvan Ghosh - Unity Biotechnology, Inc. - CEO & Director
Thank you, Matt. Great to be here. As you know, we're developing therapeutics to address aging-related diseases with our lead program being in ophthalmology. And just as a reminder for those dialing in, the lead program is UBX1325, which is being developed for DME and AMD.
UNITY Biotechnology Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers